Amount of increase (decrease) in the lessee's right to use underlying asset under operating lease.

No definition available.

Name:	clym_IncreaseDecreaseInOperatingLeaseAssets
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of reduction in milestone payments due upon performing specified services.

+ References

No definition available.

+ Details

Name:	clym_MilestonePaymentAmountReduced
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount due from the Company upon achievement of specified milestones, as part of a license agreement.

+ References

No definition available.

+ Details

Name:	clym_MilestonePayments
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount due as a result of achievement of specified milestones, as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	clym_MilestonePaymentsDue
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of upfront payment paid during the period as part of a license agreement.

+ References

No definition available.

+ Details

Name:	clym_UpfrontPaymentPaid
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in obligation for operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-SubTopic 20
-Topic 842
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:	us-gaap_IncreaseDecreaseInOperatingLeaseLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:	us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_CrhAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_ProbiogenAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=clym_MilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=clym_ManufacturingServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_AcelyrinAssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_MabworksAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_AdditionalOfficeSpaceThrough2026Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_AdditionalOfficeSpaceThrough2027Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=clym_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentManufacturingAndCommercialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details) $ in Thousands, € in Millions, £ in Millions			3 Months Ended			6 Months Ended
	Apr. 30, 2025 USD ($)	Jan. 08, 2025 USD ($)	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jan. 31, 2024 GBP (£)	Jan. 11, 2024 USD ($)	Feb. 28, 2021 EUR (€)
Gain Contingencies [Line Items]
Research and development Expense			$ 6,575		$ 1,046	$ 23,902	$ 2,137
Increase decrease in operating lease assets	$ 200
Increase decrease in operating lease liability	200					(109)	$ (249)
CRH Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments Due			0			0
ProBioGen Agreement [Member] \| Milestone [Member]
Gain Contingencies [Line Items]
Research and development Expense			800			800
ProBioGen Agreement [Member] \| Manufacturing Services [Member]
Gain Contingencies [Line Items]
Milestone Payment, Amount Reduced			1,200			1,200				€ 1.1
Acelyrin Asset Purchase Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments Due			0			0
Mabworks Agreement [Member]
Gain Contingencies [Line Items]
Upfront Payment Paid		$ 9,000
Milestone Payments Due			0			0
Additional Office Space Through 2026 [Member]
Gain Contingencies [Line Items]
Additional fixed payments	200
Additional Office Space Through 2027 [Member]
Gain Contingencies [Line Items]
Additional fixed payments	$ 100
Maximum [Member] \| ProBioGen Agreement [Member] \| Sales Milestones [Member]
Gain Contingencies [Line Items]
Milestone Payments			8,200			8,200				7.0
Development Regulatory and Commercial Milestones [Member] \| Maximum [Member] \| Acelyrin Asset Purchase Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments									$ 157,500
Development and Regulatory Milestones [Member] \| Maximum [Member] \| Mabworks Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments		30,000
Development Regulatory Commercial and Sales Milestones Member] \| Maximum [Member] \| CRH Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments			146,300			146,300		£ 106.8
Development Manufacturing and Commercial [Member] \| Maximum [Member] \| ProBioGen Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments			$ 11,700			$ 11,700				€ 10.0
Commercial Milestones [Member] \| Maximum [Member] \| Mabworks Agreement [Member]
Gain Contingencies [Line Items]
Milestone Payments		$ 832,000
Research and Development Expense [Member] \| Mabworks Agreement [Member]
Gain Contingencies [Line Items]
Upfront Payment Paid				$ 9,000